GFPT2
Basic information
Region (hg38): 5:180300698-180353336
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GFPT2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 35 | 36 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 35 | 6 | 1 |
Variants in GFPT2
This is a list of pathogenic ClinVar variants found in the GFPT2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-180301546-C-T | GFPT2-related disorder | Likely benign (Jun 18, 2021) | ||
5-180302440-C-G | not specified | Uncertain significance (Oct 26, 2022) | ||
5-180302476-C-T | not specified | Uncertain significance (Dec 06, 2022) | ||
5-180302555-G-A | Likely benign (Apr 05, 2018) | |||
5-180304777-G-A | not specified | Uncertain significance (Feb 06, 2023) | ||
5-180304876-G-T | not specified | Uncertain significance (Dec 28, 2023) | ||
5-180304879-C-T | not specified | Uncertain significance (Sep 06, 2022) | ||
5-180304901-G-C | not specified | Uncertain significance (Oct 26, 2021) | ||
5-180304926-A-C | not specified | Uncertain significance (Jun 18, 2024) | ||
5-180304928-C-G | not specified | Uncertain significance (Aug 20, 2023) | ||
5-180307241-T-G | not specified | Uncertain significance (Mar 28, 2023) | ||
5-180312451-G-A | not specified | Uncertain significance (Jul 13, 2022) | ||
5-180313818-C-T | not specified | Uncertain significance (May 09, 2023) | ||
5-180313869-G-A | not specified | Uncertain significance (Jul 14, 2021) | ||
5-180313880-C-T | not specified | Uncertain significance (Nov 21, 2022) | ||
5-180313899-C-T | not specified | Uncertain significance (Jul 26, 2021) | ||
5-180313940-G-A | not specified | Uncertain significance (May 30, 2024) | ||
5-180313949-G-A | not specified | Uncertain significance (Oct 05, 2021) | ||
5-180316354-G-C | not specified | Uncertain significance (Jan 03, 2024) | ||
5-180316365-C-T | not specified | Uncertain significance (Nov 03, 2023) | ||
5-180316383-G-A | not specified | Uncertain significance (Sep 15, 2021) | ||
5-180316457-C-T | not specified | Uncertain significance (Jun 29, 2023) | ||
5-180316763-C-T | Uncertain significance (Feb 08, 2023) | |||
5-180316810-C-T | not specified | Uncertain significance (Jan 26, 2022) | ||
5-180318854-G-A | Benign (Apr 05, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GFPT2 | protein_coding | protein_coding | ENST00000253778 | 19 | 52698 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.39e-9 | 0.999 | 124780 | 0 | 114 | 124894 | 0.000456 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.55 | 336 | 426 | 0.789 | 0.0000270 | 4457 |
Missense in Polyphen | 97 | 144.89 | 0.66947 | 1452 | ||
Synonymous | -0.648 | 188 | 177 | 1.06 | 0.0000126 | 1308 |
Loss of Function | 2.85 | 20 | 39.3 | 0.509 | 0.00000225 | 437 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000736 | 0.000721 |
Ashkenazi Jewish | 0.000100 | 0.0000993 |
East Asian | 0.000223 | 0.000222 |
Finnish | 0.000210 | 0.000186 |
European (Non-Finnish) | 0.000628 | 0.000627 |
Middle Eastern | 0.000223 | 0.000222 |
South Asian | 0.000490 | 0.000490 |
Other | 0.000500 | 0.000494 |
dbNSFP
Source:
- Function
- FUNCTION: Controls the flux of glucose into the hexosamine pathway. Most likely involved in regulating the availability of precursors for N- and O-linked glycosylation of proteins.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);Insulin resistance - Homo sapiens (human);Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Aminosugars metabolism;Fructose Mannose metabolism;Post-translational protein modification;Metabolism of proteins;UDP-<i>N</i>-acetyl-D-glucosamine biosynthesis II;Synthesis of UDP-N-acetyl-glucosamine;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation
(Consensus)
Recessive Scores
- pRec
- 0.286
Intolerance Scores
- loftool
- 0.590
- rvis_EVS
- -0.82
- rvis_percentile_EVS
- 11.94
Haploinsufficiency Scores
- pHI
- 0.729
- hipred
- Y
- hipred_score
- 0.680
- ghis
- 0.556
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.736
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gfpt2
- Phenotype
- growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); craniofacial phenotype; vision/eye phenotype; skeleton phenotype; hearing/vestibular/ear phenotype;
Gene ontology
- Biological process
- fructose 6-phosphate metabolic process;UDP-N-acetylglucosamine metabolic process;UDP-N-acetylglucosamine biosynthetic process;energy reserve metabolic process;protein N-linked glycosylation;glutamine metabolic process;cellular response to leukemia inhibitory factor
- Cellular component
- cytosol
- Molecular function
- glutamine-fructose-6-phosphate transaminase (isomerizing) activity;protein binding;carbohydrate derivative binding